Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA.

Jerzy Jaroszewicz,Małgorzata Pawłowska,Krzysztof Simon,Dorota Zarębska-Michaluk,Beata Lorenc,Jakub Klapaczyński,Magdalena Tudrujek-Zdunek,Marek Sitko,Włodzimierz Mazur,Ewa Janczewska,Katarzyna Paluch,Dorota Dybowska,Iwona Buczyńska,Agnieszka Czauż-Andrzejuk,Hanna Berak,Rafal Krygier,Maciej Piasecki,Beata Dobracka,Jolanta Citko,Anna Piekarska,Łukasz Socha,Zbigniew Deroń,Olga Tronina,Łukasz Laurans,Jolanta Białkowska,Krzysztof Tomasiewicz,Waldemar Halota,Robert Flisiak

Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA.

2020

The aim of the study was to analyze the prevalence and clinical characteristics of HCV/HBV coinfection and to evaluate the rate of HBV-reactivation during anti-HCV therapy in large real-world study...

Keywords:

Cohort
HBsAg
Medicine
Coinfection
Virology
hbv reactivation
anti hbc

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations